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Introduction: Tregs infiltrate tumors and inhibit immune responses 
against them.
Methods: We investigated subpopulations of Foxp3+ CD4 T cells 
previously defined by Miyara et al. (Immunity 30, 899–911, 2009) in 
peripheral blood mononuclear cells (PBMCs) and tumor infiltrating 
lymphocytes (TILs) in lung cancer. We also showed that Tregs in healthy 
donors that express CCR4 could be efficiently eliminated in vitro by 
cotreatment with antihuman (h) CCR4 mAb (KM2760) and NK cells.
Results: In lung cancer, the number of activated/effector Tregs and 
non-Tregs, but not resting/naive Tregs, was increased in TILs com-
pared with the number of those cells in PBMCs. The non-Treg popula-
tion contained Th2 and Th17. CCR4 expression on activated/effector 
Tregs and non-Tregs in TILs was down-regulated compared with that 
on those cells in PBMCs. Chemokinetic migration of CD25+ CD4 T 
cells containing the Treg population sorted from the PBMCs of healthy 
donors to CCL22/MDC was abrogated by pretreatment with anti-
hCCR4 mAb (KM2760). The inhibitory activity of CD25+ CD127dim/− 
CD4 Tregs on the proliferative response of CD4 and CD8 T cells 
stimulated with anti-CD3/CD28 coated beads was abrogated by adding 
an anti-hCCR4 mAb (KM2760) and CD56+ NK cells to the culture.
Conclusions: The findings suggested the CCR4 on activated/effector 
Tregs and non-Tregs was functionally involved in the chemokinetic 
migration and accumulation of those cells to the tumor site. In vitro 
findings of efficient elimination of Tregs may give the basis for 
implementation of a clinical trial to investigate Treg depletion by 
administration of an anti-hCCR4 mAb to solid cancer patients.
Key Words: Lung cancer, Tregs, CCR4, Anti-hCCR4 mAb, Treg 
depletion.
(J Thorac Oncol. 2015;10: 74–83)
Infiltration of Tregs to local tumor sites has been shown in various murine and human tumors.1 Tregs inhibit immune 
responses against tumors and also diminish the immunother-
apeutic effects which activate host immune responses.2,3 The 
CD8 T cells to Tregs ratio correlated with a favorable prognosis 
in some human cancers.4,5 Tregs appeared to inhibit the prim-
ing of CD8 and also CD4 T cells by preventing the maturation 
of dendritic cells in tumor-draining lymph nodes.6 Depletion 
of Tregs facilitated the induction of antitumor responses.7 
Two main populations of Foxp3+ Tregs have been identified: a 
“naturally occurring” (n) Treg which differentiates within the 
thymus during T-cell ontogenesis and an “induced” (i) Treg 
which develops in the periphery from conventional CD4 T 
cells.8 Conversion of CD4 T cells into iTregs occurs via various 
mechanisms involving the exposure to transforming growth 
factor beta (TGFβ) and other inhibitory cytokines, interleukin 
(IL)-6 or IL-10, and the interaction with dendritic cells.9
The accumulation of Tregs is mainly due to chemo-
kine gradients. Chemokine receptors such as CCR4, CCR5, 
CCR6, CCR7, and CCR8 are responsible for Treg migration 
to tumor tissues, and also inflammatory sites and lymph nodes 
in response to various CC chemokines.10 Of those, Tregs 
preferentially express CCR4 as compared with conventional 
T cells.11 Moreover, CCR4-expressing Tregs represent active 
Tregs with strong inhibitory activity. The involvement of 
CCR4- and CCR4-associated chemokines, CCL17/TARC and 
CCL22/MDC, in Treg migration have been documented.12,13 
Tumor cells or intratumor myeloid cells produce CCL17/
TARC and CCL 22/MDC.
Foxp3 is a key transcription factor for CD4 Tregs.14 
Miyara et al.15 reported that human Foxp3+ CD4 T cells were 
composed of three functionally and phenotypically distinct 
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subpopulations.15 CD45RA+ Foxp3lo resting/naive Tregs and 
CD45RA− Foxp3hi activated/effector Tregs were suppressive, 
whereas a CD45RA− Foxp3lo population was made up of non-
suppressive, non-Tregs.
In this study, we investigated the frequency of these 
three subpopulations in peripheral blood mononuclear cells 
(PBMCs) and tumor infiltrating lymphocytes (TILs) in lung 
cancer, and showed the accumulation of activated Tregs and 
also non-Tregs in the tumor microenvironment. We also 
examined the expression of CCR4 on these subpopulations 
and of chemokines in monocytes to clarify the mechanisms 
of Treg accumulation in lung cancer. Furthermore, we showed 
efficient Treg depletion by an anti-hCCR4 mAb (KM2760) 
and suggested its potential use in solid cancer patients.
MATERIALS AND METHODS
Patients and Clinical Samples
For preparation of a lung cancer tissue microarray (TMA), 
384 specimens including 204 adenocarcinomas, 114 squamous 
cell carcinomas, 4 large cell carcinomas, 16 small cell carcino-
mas, 8 adenosquamous cell carcinomas and 4 others, and 34 
metastatic tumors were used. Tumors were surgically removed 
from 384 patients who visited the Toyama University Hospital 
from December 1979 to May 2006. Some patients received 
chemotherapy or radiation therapy before surgery. For Treg 
analysis, PBMCs and tumor specimens were obtained from 20 
patients with lung cancer who underwent surgery at Kawasaki 
Medical School Hospital from March 2012 to March 2014. For 
T-cell migration and proliferation analysis, PBMCs from three 
healthy donors were used. Peripheral blood or tumor specimens 
were obtained from healthy donors or patients after obtaining 
informed consent. These studies were approved by the ethics 
committee of Toyama University Hospital (IRB no. 19-12) and 
Kawasaki Medical School Hospital (IRB no. 603–6) and con-
ducted in accordance with the Declaration of Helsinki.
Immunohistochemistry (IHC)
The TMA was prepared for two tumor nests in each sam-
ple punched out (core size, 0.6 mm) from formalin-fixed paraf-
fin-embedded tumor tissues. For staining, a 4 μm thick section 
on a slide was used. To stain CCR4, a POTELIGEO TEST IHC 
(Kyowa Medex, Tokyo, Japan) was used. Briefly, after being 
deparaffinized, a tissue section was put in an oven for antigen 
retrieval for 40 minutes at 98°C. Endogenous peroxidase was 
blocked by adding 1 N HCl for 10 minutes. Mouse anti-hCCR4 
mAb (KM2160; Kyowa Hakko Kirin, Tokyo, Japan) (1:200) 
was then added and incubated for 30 minutes. As a second anti-
body, a peroxidase-conjugated goat antimouse immunoglobu-
lin (IgG) (1:1000) was added and incubated for 30 minutes. 
For staining CD4 and Foxp3, a rabbit anti-hCD4 mAb (clone 
EPR6855; abcam, Cambridge, UK) (1:100) and a mouse anti-
hFoxp3 mAb (clone 236A/E7; abcam) (1:100), respectively, 
were added and incubated for 30 minutes. For doublestaining 
of CCR4 and CD4, a mouse/rabbit multiplex detection system 
(MP-001; Diagnostic Biosystems, Pleasanton, CA) was used. 
For staining of CCL17/TARC, goat anti-hCCL17/TARC (1:40) 
was used and incubated for 60 minutes. Simple stain MAX-PO 
(G) (414161; Nichirei, Tokyo, Japan) was used as a second 
antibody and incubated overnight. For staining of CCL22/
MDC, a mouse anti-hCCL22/MDC mAb (clone 57226; R&D 
Systems, Minneapolis, MN) (1:50) was used and incubated 
overnight. For staining of CD163, a mouse anti-hCD163 mAb 
(clone 10D6; abcam) (1:1) was used and incubated for 30 min-
utes. As a second antibody, Envision Dual Link reagent (Dako, 
Glostrup, Denmark) was used and incubated for 30 minutes. 
Counterstaining was done with hematoxylin.
IHC Scoring of TMA
Interstitial cells and tumor cells were scored separately 
by the grade of distribution and intensity.16 For grading distri-
bution, 0 for 0%; 1 for 1 to 50%; and 2 for 51 to 100% were 
used. For grading intensity, 0 for no staining; 1 for weak stain-
ing; 2 for moderate staining, and 3 for marked staining were 
used. The mean of the sum of distribution and intensity scores 
from two distinct tumor TMA histospots was used as the 
definitive IHC score. Scores exceeding 2 (≥2.5) were defined 
positive. Scoring was performed by a pathologist.
Isolation of TILs
TILs were freshly isolated from lung cancer tissues using 
a Medimachine (BioLab, Osaka, Japan). Briefly, the tumor tis-
sue was minced into pieces (<1 mm3) and placed on a stainless 
steel screen with approximately 100 hexagonal holes, each sur-
rounded by six microblades, in a sterile Medicon polyethylene 
chamber (BioLab) in 1 ml medium. A rotating screen brings 
the tissue into contact with the blades and it is homogenized. A 
Medicon with 50 μm separator screens was used. The proce-
dure was repeated 3 times for 60 seconds at a constant speed of 
100 rpm. Cells were collected after filtration using filters with 
a 50-µm pore size and then TILs were isolated.
Flow Cytometry
PBMCs and TILs were isolated by density gradient 
centrifugation using a Histo-Paque 1077 (Sigma–Aldrich, St. 
Louis, MO). Freshly isolated PBMCs or TILs were incubated 
with a mAb for 20 minutes at 4°C. The following mAbs were 
used: Anti-hCD3-V450 (clone UCHT1; BD Horizon, BD 
Bioscience, San Jose, CA), anti-hCD4-V500 (clone RPA-T4; 
BD Horizon), anti-hCD8-APC (clone RPA-T8; BD Pharmingen, 
BD Bioscience, San Jose, CA), anti-hCCR4-PerCP/Cy5.5 
(clone 1G1; BD Pharmingen), anti-hFoxp3-Alexa Fluor 488 
(clone 259D/C7; BD Pharmingen), and anti-hCD45RA-APC/
H7 (clone HI100; BD Pharmingen). Intracellular Foxp3 stain-
ing was performed using a Human Foxp3 buffer set (BD 
Pharmingen) according to the manufacturer’s instructions. With 
each sample, an isotype-matched control Ab was used to deter-
mine the positive and negative cell populations. Analysis was 
done by fluorescence activated cell sorting (FACS) Canto II.
CFSE Labeling
A carboxyfluorescein diacetate succinimidyl ester 
(CFSE) stock (10 mM in dimethyl sulfoxide (DMSO): 
Molecular Probes, Eugene, OR) stored at −30°C was thawed 
and diluted in phosphate buffered saline (PBS). The CD4 or 
CD8 T cells (5 × 106 cells/ml) in 0.1% bovine serum albumin 
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(BSA) PBS were incubated with 10 µM CFSE for 10 minutes 
at 37°C, diluted by five volumes of cold 0.1% BSA PBS, and 
kept on ice for 5 minutes. Cells were washed three times and 
used for experiments.
Cell Migration Assay
The cell migration was examined using EZ-TAXIScan 
(Effector Cell Institute, Tokyo, Japan) apparatus.17,18 Two 
compartments of a cell migration assay chamber in etched 
silicon were connected by a 4 µm deep microchannel on a 
flat glass plate in the chamber. A glass coverslip was placed 
onto the glass plates. A reproducible chemoattractant gradient 
was formed in the microchannel without medium flow. The 
holder was filled with AIM V (Invitrogen, Carlsbad, CA) sup-
plemented with 2.5% heat-inactivated pooled human serum 
and maintained at 37°C. CD25+ CD4 T cells (1 × 105 cells in 
1 µl) sorted from PBMCs which were left untreated or treated 
with anti-hCCR4 mAb (KM2760; Kyowa Hakko Kirin) using 
FACS Aria were injected into one compartment and 1 µl of 
CCL22/MDC (500 µg/ml; R&D Systems) solution into the 
other compartment. The migration of each cell in the chan-
nel was traced at time-lapse intervals using a charge coupled 
device (CCD) camera and recorded every 1 minute for 60 
minutes. The cells that crossed a fixed gate were counted using 
a TAXIScan Analyzer (Effector Cell Institute).
To examine blocking activity of anti-hCCR4 mAb 
(KM2760) on migration, 24-well Transwell chemotaxis plates 
(3 µm pore size; Corning Costar, Corning, NY) were used. 
CD4 T cells (1 × 105) were placed in the upper chamber of a 
Transwell plate. Various concentrations of anti-hCCR4 mAb 
(KM2760) were added to both the upper and lower cham-
bers. Then, CCL22/MDC (100 ng/ml) was added to the lower 
chamber and incubated for 4 hours at 37°C. After incubation, 
all cells in the lower chamber were collected and the number 
of cells was counted with an FACS Canto II.
Proliferation Assay
To obtain Tregs, a regulatory T-cell isolation Kit II 
(Miltenyi Biotec, Bergisch Gladbach, Germany) was used. 
CD127dim/− CD4 T cells were indirectly purified from PBMCs 
of healthy donors using biotin-conjugated antibodies against 
CD8, CD19, CD123, and CD127 with antibiotin antibody-
coated magnetic beads. CD25+ CD127dim/− CD4 Tregs were 
then purified and CD25− CD127dim/− CD4 T cells were used 
as control cells. CD56+ NK cells, and CD4 and CD8 T cells 
were purified from PBMCs also using antibody-coated mag-
netic beads (Miltenyi Biotec). Tregs (1 × 104) and CD56+ 
NK cells (1 × 104) were incubated overnight with or without 
anti-hCCR4 mAb (KM2760) at a concentration of 10 µg/ml 
in 96-well culture plates. The cells in the plates were washed 
three times and anti-hCD3/28 beads (Dynabeads Human 
T-Activator CD3/CD28, Invitrogen) were added to the cul-
ture and incubated for 8 hours for suppressor cell stimulation. 
CFSE-labeled responder cells (1 × 104/well) were then added 
and stimulated by anti-CD3/28 beads. After 24 hours, anti-
CD3/28 beads were removed and the cells were kept cultured 
for another 3 to 4 days. After culture, the cells were harvested 
and CFSE dilution was analyzed with an FACS Canto II. The 
medium used was AIM V (Invitrogen) supplemented with 5% 
heat-inactivated pooled human serum, 2 mM L-glutamine, 100 
IU/ml penicillin, and 100 µg/ml streptomycin.
RESULTS
Subpopulations of Foxp3+ CD4 T Cells and 
Expression of CCR4 on Those Cells in PBMCs 
and TILs From Lung Cancer Patients
Subpopulations of Foxp3+ CD4 T cells and expression 
of CCR4 on those cells in PBMCs and TILs from lung cancer 
patients were analyzed. The characteristics of 20 patients inves-
tigated are shown in Table 1. As shown in Figure 1, Foxp3+ 
CD4 T cells were classified as three subpopulations: CD45RA+ 
Foxp3lo resting/naive Tregs (Fr 1), CD45RA− Foxp3hi activated/
effector Tregs (Fr 2), and CD45RA− Foxp3lo non-Tregs (Fr 3), 
as described by Miyara et al.15 The mean ratios of resting/naive 
and activated/effector Tregs, and non-Tregs in CD4 T cells in 
PBMCs from 20 lung cancer patients were 0.6, 1.6, and 4.1%, 
respectively. However, the mean ratios of resting/naive and 
activated/effector Tregs, and non-Tregs in CD4 T cells in TILs 
were 0.5, 9.9, and 9.8%, respectively. The ratios of activated/
effector Tregs and non-Tregs, but not resting/naive Tregs, in 
CD4 T cells in TILs were higher than those in PBMCs.
TABLE 1.  Patient Characteristics (n = 20)
Characteristics Patients
Age, years
  Median 76.5
  Range 58–85
  ≥65 16 80 (%)
Sex
  Male 17 85
  Female 3 15
BMI (kg/m2) 22.6 ± 2.6
Smoking status
  Never 4 20
  Former 13 65
  Current 3 15
  Pack-years 46.8 ± 37.8
FEV
1
/FVC (%) 68.0 ± 10.3
FEV
1
 % predicted 106.4 ± 17.1
Pathologic stage
  IA 6 30
  IB 4 20
  IIA 6 30
  IIB 0 0
  IIIA 4 20
Histology
  Adenocarcinoma 12 60
  Squamous cell 
carcinoma
5 25
  Large cell carcinoma 2 10
  Adenosquamous cell 
carcinoma
1 5
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The CCR4 expression on those populations was then 
determined. The mean ratios of CCR4+ cells in resting/naive 
and activated/effector Tregs, and non-Tregs in PBMCs were 
13.0, 88.7, and 65.6%, respectively. However, the mean ratios 
of CCR4+ cells in activated/effector Tregs and non-Tregs in 
TILs were 34.6 and 28.5%, respectively. Insufficient resting/
naive Tregs were available for the analysis in TILs. The ratios 
of CCR4+ cells in activated/effector Tregs and non-Tregs in 
TILs were lower than those in PBMCs.
Detection of CCR4- and CCL22/
MDC-Expressing Cells in Lung 
Cancer by IHC Using a TMA
CCR4-, CCL17/TARC-, and CCL22/MDC-expressing 
cells in lung cancer were analyzed by IHC using TMA. For 
evaluation, the staining score was determined by the sum of 
scores of distribution and intensity (See Materials and Methods 
Section). Two TMA spots were examined in each sample and 
the mean score was calculated for the definitive score. A 
definitive score exceeding 2 (≥2.5) was defined as positive. As 
shown in Figure 2A and B, CCR4-expressing stroma infiltrat-
ing lymphocytes were detected in 78 (20.3%) of 384 samples 
and CCR4-expressing tumor cells were detected in only 1 
(0.3%). CCL17/TARC-expressing stroma infiltrating mono-
cytes were detected in 5 (1.3%) of 384 samples and CCL17/
TARC-expressing tumor cells were detected in 2 (0.5%). 
CCL22/MDC-expressing stroma infiltrating monocytes were 
detected in 117 (30.5%) of 384 samples and CCL22/MDC-
expressing tumor cells were detected in none. As shown in 
Figure 3A, CCR4-stained lymphocytes were mostly CD4 and 
some of those cells were also positive for Foxp3. As shown in 
Figure 3B, some CCL22/MDC-expressing cells were likely to 
be CD163-positive M2 macrophages. CCR4 expression was 
correlated with CCL22/MDC (Figure 3C).
By enzyme-linked immunosorbent assay using plasma 
and malignant pleural effusion, we detected a significant 
amount of CCL17/TARC in 1 patient and CCL22/MDC in 
several patients out of a total 17 lung cancer patients in a sepa-
rate analysis (data not shown). Predominance of CCL22/MDC 
compared with CCL17/TARC in lung cancer was consistent 
with the IHC results.
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FIGURE 1.  Analysis of subpopulations of Foxp3+ CD4 T cells and expression of CCR4 on those cells in PBMCs and TILs from 
lung cancer patients. A, classification of Foxp3+ CD4 T cells as CD45RA+ Foxp3lo resting/naive Tregs (Fr 1), CD45RA− Foxp3hi acti-
vated/effector Tregs (Fr 2) and CD45RA− Foxp3lo non-Tregs (Fr 3). B, representative dot plots showing subpopulations of Foxp3+ 
CD4 T cells in PBMCs and TILs and histograms showing the CCR4 expression on those cells using anti-hCCR4 mAb (1G1) and 
the isotype-mached control Ab (gray). Figures indicate % positive cells. C, ratios of resting/naive and activated/effector Tregs, 
and non-Tregs in CD4 T cells (left panel) and CCR4 expression on those cells (right panel) in PBMCs and TILs from 20 lung 
cancer patients. Horizontal bar, mean value. Statistical analysis was done by the Mann-Whitney U test (**** p < 0.0001). Each 
dot indicates a single patient.
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Efficient migration of a CCR4+CD25+ CD4 T-cell 
population in PBMCs to the CCL22/MDC gradient 
and elimination of migrating cells by adding an 
anti-hCCR4 mAb (KM2760) to the culture
Antihuman (h) CCR4 mAb (KM2760) is a defucosyl-
ated antibody developed by the Potelligent technology and 
it has been shown to exert antibody-dependent cellular-cyto-
toxicity (ADCC) against CCR4-expressing cells by using NK 
cells as effector cells.19 We examined the migration of CD25+ 
CD4 T cells sorted from PBMCs which were left untreated or 
treated with anti-hCCR4 mAb (KM2760) to the CCL22/MDC 
gradient using EZ-TAXIScan apparatus. Expression of CCR4 
on sorted cells was confirmed with an FACS Canto II (data 
not shown). As positive and negative controls for migration, 
CCR4+ CD4 T cells and CCR4− CD4 T cells sorted from anti-
hCCR4 mAb (1G1) (with no ADCC activity) and anti-hCD4 
mAb-treated PBMCs were used. As shown in Figure 4, effi-
cient migration to the CCL22/MDC gradient was observed in 
a CD25+ CD4 T-cell population sorted from anti-hCCR4 mAb 
(KM2760)-untreated PBMCs. Migrating cells were markedly 
diminished in a CD25+ CD4 T-cell population sorted from 
anti-hCCR4 mAb (KM2760)-treated PBMCs.
We further examined whether an anti-hCCR4 mAb 
(KM2760) could directly block the migration of CD4 T cells 
HE CCR4 CCL17/TARC CCL22/MDC
1/384 (0.3%) 2/384 (0.5%)
117/384 (30.5%)
0/384 (0%)Tumor
Stroma 5/384 (1.3%)78/384 (20.3%)
A
B
CCR4
CCL22
D+I=0+0 D+I=1+1 D+I=1+2 D+I=1+3
FIGURE 2.  Analysis of CCR4-, CCL17/TARC- and CCL22/MDC-expressing cells in lung cancer by Immunohistochemistry (IHC) 
using a tissue microarray (TMA). A, staining score was determined by a sum of scores of distribution (D) and intensity (I) (See 
Materials and Methods Section). Representative intensity (I) scoring with density (D) score 1 for CCR4 and CCL22 are shown. 
Two TMA spots were examined in each sample and the mean score was calculated for the definitive score. A definitive score 
exceeding 2 (≥2.5) was considered positive. Scale bar denotes 100 µm for low magnification and 50 µm for high magnifica-
tion (inset). B, representative staining of TMA with CCR4 (score 3), CCL17/TARC (score 0) and CCL22/MDC (score 3) and the 
number of positive samples for stroma-infiltrating cells and tumor cells in the total of 384 samples are shown. HE, hematoxylin/
eosin. Scale bar denotes 100 µm.
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to the CCL22/MDC gradient without NK cells using Transwell 
plates. As shown in Figure 4C, anti-hCCR4 mAb (KM2760) 
had no blocking effect on migration of CD4 T cells or any 
Treg population in a range of antibody concentrations.
Inhibition of CD3/CD28-mediated proliferative 
response of CD4 and CD8 T cells by CD25+ CD4 
Tregs and abrogation of inhibition by treatment 
with an anti-hCCR4 mAb (KM2760)
We then examined inhibition of CD4 and CD8 T-cell 
proliferation by Tregs and abrogation of inhibition by the 
treatment of Tregs with an anti-hCCR4 mAb (KM2760). 
CD127dim/− CD4 T cells were indirectly purified from PBMCs 
of healthy donors using biotin-conjugated antibodies against 
CD8, CD19, CD123, and CD127 with antibiotin antibody-
coated magnetic beads. CD25+ CD127dim/− CD4 Tregs were 
then purified and CD25− CD127dim/− CD4 T cells were used as 
control cells. CD56+ NK cells, and CD4 and CD8 T cells were 
purified from PBMCs also using antibody-coated magnetic 
beads. Tregs (1 × 104) and CD56+ NK cells (1 × 104) were incu-
bated overnight with or without anti-hCCR4 mAb (KM2760) 
at a concentration of 10 µg/ml in 96-well culture plates. After 
washing the cells in the plates, anti-CD3/CD28 beads were 
added. The CFSE-labeled responder CD4 and CD8 T cells 
were then added and proliferation was determined after 5 to 6 
days. As shown in Figure 5, proliferation of either CD4 or CD8 
T cells stimulated by anti-CD3/CD28 beads was inhibited by 
culturing with CD25+ CD127dim/− CD4 Tregs and CD56+ NK 
cells without anti-hCCR4 mAb (KM2760). The inhibition was 
abrogated in the culture with an anti-hCCR4 mAb (KM2760).
DISCUSSION
Foxp3+ CD4 T cells were composed of three distinct pop-
ulations and classified according to the expression of CD45RA 
and Foxp3 on those cells.15 In this study, we showed that the 
ratios of activated/effector Tregs and non-Tregs in Foxp3+ CD4 
T cells were higher in TILs obtained from surgically removed 
specimens than those in PBMCs in lung cancer patients. The 
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FIGURE 3. A, Immunohistochemistry (IHC) staining of tissue microarray (TMA) with anti-CCR4, anti-CD4, and anti-Foxp3 in 
lung cancer tissue. In double staining of CCR4 and CD4, CCR4 is stained brown and CD4 is stained red. Arrows indicate double-
stained cells. ATL is a positive control. Staining of CCR4 and Foxp3 are done on serial sections. Arrows show the cells stained 
with either mAb. Scale bar denotes 100 µm. B, IHC staining of serial sections with anti-CCL22 and anti-CD163. Arrows show the 
cells stained with either mAb. C, Correlation of CCR4 with CCL22 score. CCL22− (score 0–2): n = 267, CCL22+ (score ≥ 2.5): n 
= 117. CCR4 score is the mean value with the error bar showing 95% confidence interval. Statistical analysis was done by the 
Mann-Whitney U test.
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findings suggested that the activated/effector Tregs and also 
non Tregs appeared to accumulate in the tumor from PBMCs. 
No increase in resting/naive Tregs in TILs suggests conversion 
from resting/naive Tregs to activated/effector Tregs in the tumor 
as described previously.15,20 The non Treg population contains 
Th2 and Th17 that could be involved in effector mechanisms in 
tumors.1,15 In our analysis of TILs from 11 lung cancer patients, 
CD45RA− Foxp3lo, a non Treg population contained CRTH2 
(CD294)-positive Th2 cells (approximately 9%) and CCR6-
positive Th17 cells (approximately 14%), although the rest of 
cells were not clearly analyzed. Miyara et al. reported detection 
of transcription factor RAR-related orphan receptor C (RORC) 
and secretion of IL-17, and also secretion of interferon gamma 
(IFNγ) in stimulation with PMA/ionomycin with the cells in 
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of migrating cells by adding an anti-CCR4 (KM2760) mAb to the culture. A, migration of CD25+ CD4 T cells (CD25+KM− and 
CD25+KM+) sorted from PBMCs which were left untreated or treated with anti-hCCR4 mAb (KM2760), respectively, using FACS 
Aria to the CCL22/MDC gradient was investigated using EZ-TAXIScan apparatus. CCR4+ CD4 T cells and the CCR4− CD4 T cells 
sorted from anti-hCCR4 (1G1) mAb (without ADCC activity) and anti-hCD4 mAb-treated PBMCs were used as positive and 
negative controls, respectively, for migration. The results are the mean ± SD of duplicates. B, the % migrating cells to CCL22/
MDC counted at 30 minutes in the assay. The results are the mean ± SD of three individuals. Statistical analysis was done by 
Welch’s t test (** p < 0.01, **** p < 0.0001). C, blocking of Treg migration by an anti-hCCR4 (KM2760) mAb. Purified CD4 T 
cells (1 × 105) were placed in the upper chambers and CCL22 (100 ng/ml) was placed in the lower chambers of Transwell plates. 
A different amount of anti-hCCR4 (KM2760) mAb was present in the upper and lower chambers during the migration assay. 
After incubation for 4 hours, all cells in the lower chambers were collected and the number of cells was counted with a FACS 
Canto II. FACS dot plots showed subpopulations of Foxp3+ CD4 T cells (top). Numbers in the dot plot panel denote % of rest-
ing/naive Tregs, non-Tregs and activated/effector Tregs in the migrated Foxp3+ CD4 T cells from top to bottom. Migration of 
non-Tregs and activated/effector Tregs to CCL22/MDC was observed, but no blocking of migration by addition of KM2760 was 
observed. Numbers of migrating CD4 T cells (bottom left) and activated/effector Tregs (bottom right) are shown. The results 
are the mean ± SD of triplicate experiments. Statistical analysis was done by the Welch’s t test for two groups and by ANOVA for 
multiple groups (** p < 0.01). No blocking of migration was observed.
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the population.15 Thus, a small fraction of Th2, Th17, or IFNγ-
producing cells was detected in the CD45RA− Foxp3 low posi-
tive, non-Treg fraction (Fr 3), although the majority of those 
cells were Foxp3-negative cells.
With regard to Th17 cells, it has recently been shown that 
the frequency of these cells secreting IL-17 was increased in 
patients with different types of tumors,21 including lung can-
cer.22 The density of intratumoral IL-17-positive cells in primary 
human NSCLC was inversely correlated with patient outcome 
and correlated with the smoking status of the patients.23
We also showed that CCR4 expression on activated/
effector Tregs and also non-Tregs in TILs was down-regulated 
compared with that on those cells in PBMCs. It was noticed 
that chemokine receptors, including CCR4, were down-reg-
ulated quickly after interaction with the respective chemo-
kines.24 These findings suggested that CCR4 was functionally 
involved with chemotactic migration and accumulation of 
activated/effector Tregs and non-Tregs to the tumor sites.
We demonstrated that CCR4-expressing lymphocytes 
infiltrated in tumor tissue and some of them were likely 
Foxp3+ CD4 T cells as judged by IHC using TMA. CCR4-
stained lymphocytes were detected in only 20% of the tumor 
tissues of 384 samples examined, whereas flow cytometric 
analysis showed that activated/effector Tregs were detected 
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D, the results in (B) are shown as the mean ± SD of triplicate experiments. Statistical analysis was done by Welch’s t test (** p < 
0.01, *** p < 0.001).
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in TILs from most of the 20 lung cancer patients we investi-
gated. Detection of CCR4-expressing cells at a low frequency 
in TMA appeared to be due to the limited area of tumor tissue 
prepared for TMA and/or low sensitivity of IHC.16
Anti-hCCR4 mAb (KM2760) is a defucosylated chi-
meric mAb produced by Potelligent technology and has been 
shown to have more than 100 times stronger ADCC activity 
than the original antibody.19 Leukemic cells in adult T-cell leu-
kemia (ATL) express CCR4 on their surfaces and cytotoxicity 
of anti-hCCR4 mAb (KM2760) to those cells has been dem-
onstrated.25 Yamamoto et al.26 reported that administration of 
even a small dose (0.1 mg/kg) of humanized anti-hCCR4 mAb 
(KW-0761) efficiently eliminated leukemia cells in the periph-
eral blood in ATL patients in clinical trials.26 In this study, we 
showed that activated/effector Tregs also express CCR4 on 
their surface and that those cells could be efficiently eliminated 
in vitro by treatment with an anti-hCCR4 mAb (KM2760) by 
ADCC with NK cells. Migration of a CD25+ CD4 Treg popula-
tion sorted from PBMCs in healthy donors to a CCL22/MDC 
gradient was abrogated by the pretreatment of PBMCs with an 
anti-hCCR4 (KM2760) mAb. The inhibition of the prolifera-
tive response of CD4 and CD8 T cells stimulated with anti-
CD3/CD28-coated beads by CD25+CD127dim/− CD4 Tregs was 
abrogated by adding anti-hCCR4 mAb (KM2760) and CD56+ 
NK cells to the culture. These in vitro findings of efficient 
elimination of Tregs in a migration assay and in a T-cell prolif-
eration assay may give the basis for implementation of clinical 
trials focusing on depletion of Tregs by administration of anti-
hCCR4 mAb to cancer patients with various solid tumors.
In this study, we showed that an anti-hCCR4 mAb 
(KM2760) had no direct blocking activity on the migration 
of purified CD4 T cells to the CCL22/MDC gradient by sim-
ply adding it to the culture during the assay. There is extensive 
redundancy in the binding for chemokines to chemokine recep-
tors.27 It is possible that chemokine receptors other than CCR4 
are involved in the migration to the CCL22/MDC gradient 
under the CCR4 blockade.28 Or it could simply be due to the 
lack of blocking activity for CCL22/MDC binding to CCR4.
Recently, Sugiyama et al.29 showed depletion of acti-
vated/effector Tregs and augmentation of T-cell responses 
against the NY-ESO-1 antigen by magnetic bead depletion 
using a biotin anti-CCR4 mAb (1G1) and also by simply add-
ing a mouse antihuman CCR4 mAb (KM2160) to the cul-
ture.29 In our study, we showed that a defucosylated chimeric 
KM2760 derived from KM2160 efficiently depleted Tregs by 
ADCC with NK cells as above. However, with KM2760, no 
depletion of any Treg subpopulations and no effect on their 
migration to CCL22/MDC was observed without adding NK 
cells. The difference in the direct depletion effect between 
KM2160 and KM2760 by adding to the culture could be due 
to experimental systems, especially incubation time (7 days 
in their study and 4 hours in ours) or due to loss of depleting 
activity by chimerization and defucosylation of the antibody, 
although less likely. This point should be carefully addressed 
in future studies.
Induction of immune responses by depleting Tregs has 
been reported previously.30,31 In vitro depletion of CD25+ 
cells induced activation of NY-ESO-1-specific naive CD4 
T-cell precursors in stimulation with NY-ESO-1 peptides in 
PBMCs from healthy donors and from NY-ESO-1-expressing 
melanoma patients who had no NY-ESO-1 antibodies.32 We 
previously showed that depletion of Tregs by in vivo admin-
istration of an anti-CD25 mAb (clone PC61) caused rejection 
of tumors that otherwise grew progressively in murine tumor 
models.7 However, the effect of inducing tumor rejection by 
administration of the mAb was observed only up to day 2 after 
tumor inoculation. This is probably due to the depletion of 
the effector T cells, which were generated after recognition 
of the tumor cells and express CD25 on their cell surfaces.33 
There are some reports of clinical trials on the depletion of 
CD25 Tregs using anti-CD25 or diphtheria toxin-conjugated 
IL-2 (denileukin diftitox).34,35 The results in those studies were 
controversial: successful depletion of CD25+ cells and aug-
mentation of the tumor immune response in one study,36 but 
no effect in the others.
We are currently conducting a phase I clinical trial 
administering humanized anti-hCCR4 mAb (KW-0761) 
to patients with various solid tumors. Depletion of CCR4-
expressing activated/effector Tregs in PBMCs will result in 
depletion of either CCR4-expressing or nonexpressing acti-
vated/effector Tregs in the tumor if they migrate from the 
peripheral blood. On the other hand, the findings that high 
and low frequencies of CCR4-expressing cells in activated/
effector Tregs and resting/naive Tregs, respectively, in PBMCs 
may suggest that the CCR4 expression is correlated with Treg 
function, and only the CCR4-expressing population represents 
functional Tregs in TILs, although this remains to be clarified. 
Our preliminary results show efficient depletion of CCR4-
expressing activated/effector Tregs in PBMCs, although those 
cells in the TILs were not analyzed.
Off-target effects could occur due to anti-CCR4 mAb 
therapy. CCR4 is expressed on Th2 and Th17 cells other than 
Tregs, but not on Th1 cells (data not shown). Depletion of 
these cells may cause impaired antibody and cellular responses 
against infection. CD8 and monocytes express no CCR4 (our 
unpublished observation).29 Studies on ATL/ATLL patients 
and our preliminary study on solid tumor patients showed that 
eruption controllable by steroids probably caused by autoim-
munity was commonly observed, whereas infection was rare.26
CCR4 expression on tumor cells is controversial. 
Frequent expression was reported with head and neck cancer37 
and moderate expression was reported with other cancers.38,39 
In lung cancer, however, IHC analysis of TMA in this study 
showed that CCR4 expression on tumor cells was observed 
in only 1 of 384 specimens. These findings suggest that the 
ADCC caused by anti-hCCR4 mAb (KW-0761) acts against 
CCR4-expressing lymphocytes, but not tumor cells, in lung 
cancer.
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